The "2023 Top 100 Chinese Pharmaceutical Industry Enterprises" list was recently released at the 41st China Pharmaceutical Industry Information Annual Conference. Multiple companies from the Beijing Economic-Technological Development Area (Beijing E-Town), such as Bayer Healthcare, Tide Pharmaceutical, and Youcare Pharmaceutical Group, made it onto the list.

Bayer Healthcare ranked 14th on the "2023 Top 100 Chinese Pharmaceutical Industry Enterprises" list and has been on the list for 12 consecutive years. Focusing on the Chinese market, Bayer's prescription drugs specialize in the treatment areas of cardiology, oncology, gynecology, hematology, and ophthalmology. It also offers a variety of influential health consumer products. Since 2009, Bayer's prescription drugs have launched 19 innovative drugs in China, totaling 36 new drugs or new indications approved.

Tide Pharmaceutical not only ranked 66th on the list but also received the award for "Best Industrial Enterprise in China for Pharmaceutical R&D Product Line in 2024". Ted Pharmaceutical focuses on four major business segments: innovative drugs, biological products, high-end formulations, and high-end medical devices, with a concentration on microcirculation, pain relief, respiratory, and oncology areas. It has developed a range of domestically and even globally leading innovative product series.

With outstanding research and development innovation capabilities and robust marketing abilities, Youcare Pharmaceutical Group ranked 79th on the list and was also honored as the "Best Industrial Enterprise in China for Pharmaceutical R&D Product Line in 2024." Youcare Pharmaceutical has focused on core indications such as cardiovascular, anti-tumor, and infectious diseases. It has a comprehensive layout in cutting-edge technology fields such as nucleic acid drugs, cell and gene therapy drugs, peptide drugs, high-end chemical drugs, and innovative traditional Chinese medicines. Through continuous innovation and iteration, the company has overcome the "bottleneck" challenges in innovative drug research and development, dedicating themselves to addressing unmet clinical needs.

Currently, Beijing E-Town has gathered over 4,900 biopharmaceutical companies, with a total output value of nearly 100 billion yuan ($14.06 billion) in the pharmaceutical and health industry, accounting for nearly half of the Beijing's total, ranking first in the city.